Lung hyperinflation in COPD: The impact of pharmacotherapy

European Respiratory Review

Volumn 15, Issue 100, 2006, Pages 85-89

  O'Donnell, D E ^a,b   Laveneziana, P ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Dynamic hyperinflation; Dyspnoea; Exercise; Respiratory mechanics

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; PLACEBO; TIOTROPIUM BROMIDE;

BREATHING MECHANICS; BREATHING MUSCLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; DYSPNEA; EXERCISE; EXPIRATORY FLOW; EXPIRATORY RESERVE VOLUME; HUMAN; HYPERINFLATION; INSPIRATORY CAPACITY; LUNG COLLAPSE; LUNG VENTILATION; LUNG VOLUME; SPIROMETRY; SYMPTOM;

EID: 34447121373     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00010006     Document Type: Conference Paper

References (33)

1. ATS/ERS Task Force. Standardization of spirometry. Eur Respir J 2005; 26: 319-338.
2. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD. Is spirometry useful? Chest 2000; 117: 42S-47S.
3. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in COPD. Am J Respir Crit Care Med 1999; 160: 524-549.
4. O'Donnell D, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004; 23: 832-840.
5. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005; 128: 1168-1178.
6. Newton M, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002; 121: 1042-1050.
7. Rabe KF, Bateman ED, O'Donnell D, Witte S, Bredenbröker D, Bethke TD. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2005; 366: 563-571.
8. 6 is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 2000; 162: 917-919.
9. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.
10. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12: 799-804.
11. O'Donnell DE, Forkert L, Webb KA. Evaluation of bronchodilator responses in patients with "irreversible emphysema". Eur Respir J 2001; 18: 914-920.
12. O'Donnell DE, Hamilton AL, Webb KA. Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol 2006; 101: 1025-1035.
13. Sciurba FC, Rogers RM, Keenan RJ, et al. Improvement in pulmonary function and elastic recoil after lung-reduction surgery for diffuse emphysema. N Engl J Med 1996; 334: 1095-1099.
14. Hyatt RE. Expiratory flow limitation. J Appl Physiol 1983; 55: 1-8.
15. Dawson SV, Elliott EA. Wave-speed limitation on expiratory flow - a unifying concept. J Appl Physiol 1977; 43: 498-515.
16. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153: 967-975.
17. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297: 1506-1510.
18. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur Respir J 2004; 24: 86-94.
19. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 2006; 130: 647-656.
20. Peters MM, Webb KA, O'Donnell DE. Combined physiological effects of bronchodilators and hyperoxia on exertional dyspnoea in normoxic COPD. Thorax 2006; 61: 559-567.
21. Diaz O, Villafranca C, Ghezzo H, et al. Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitations at rest. Eur Respir J 2000; 16: 269-275.
22. O'Donnell DE, Revill S, Webb KA. Dynamic hyperinflation and exercise intolerance in COPD. Am J Respir Crit Care Med 2001; 164: 770-777.
23. Gandevia SC. The perception of motor commands on effort during muscular paralysis. Brain 1982; 105: 151-195.
24. Chen Z, Eldridge FL, Wagner PG. Respiratory associated rhythmic firing of midbrain neurons in cats: relation to level of respiratory drive. J Physiol 1991; 437: 305-325.
25. Chen Z, Eldridge FL, Wagner PG. Respiratory-associated thalamic activity is related to level of respiratory drive. Respir Physiol 1992; 90: 99-113.
26. Davenport PW, Friedman WA, Thompson FJ, Franzen O. Respiratory-related cortical potentials evoked by inspiratory occlusion in humans. J Appl Physiol 1986; 60: 1843-1848.
27. O'Donnell DE, Webb KA. Mechanisms of dyspnea in COPD. In: Mahler DA, O'Donnell DE, eds. Dyspnea: Mechanisms, Measurement, and Management. 2nd Edn. New York, Taylor & Francis, 2005; pp. 29-58.
28. O'Donnell DE, Hong HH, Webb KA. Respiratory sensation during chest wall restriction and dead space loading in exercising men. J Appl Physiol 2000; 88: 1859-1869.
29. Zechman FR Jr, Wiley RL. Afferent inputs to breathing: respiratory sensation: In: Fishman AP, ed. Handbook of Physiology, Section 3, Volume II, Part 2: The Respiratory System. Bethesda, American Physiological Society, 1986; pp. 449-474.
30. O'Donnell DE, Chau LKL, Bertley JC, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Crit Care Med 1997; 155: 109-115.
31. van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005; 26: 214-222.
32. Donohue JF. Combination therapy for chronic obstructive pulmonary disease: clinical aspects. Proc Am Thorac Soc 2005; 2: 272-281.
33. van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006; 129: 509-517.